

CITATION REPORT

List of articles citing

Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol

DOI: 10.2165/00003088-200544120-00003
Clinical Pharmacokinetics, 2005, 44, 1227-46.

Source: <https://exaly.com/paper-pdf/39421332/citation-report.pdf>

Version: 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
228	Careful management can reduce the risk of bleeding in elderly patients receiving vitamin K antagonist (VKA) therapy. 2006 , 22, 23-26		
227	Interaction between lopinavir/ritonavir and warfarin. 2007 , 177, 357-9		33
226	Probable warfarin-simvastatin interaction. 2007 , 41, 1292-5		32
225	Plasma S/R ratio of warfarin co-varies with VKORC1 haplotype. 2007 , 18, 293-6		6
224	Understanding and treating disorders of the clotting system. 2007 , 20, 21-6		3
223	A clinical algorithm to predict the loading dose of phenprocoumon. 2007 , 120, 921-5		1
222	Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany. 2007 , 7, 199-217		11
221	Varenicline: progress in smoking cessation treatment. 2007 , 8, 1757-67		10
220	Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. 2007 , 23, 1131-8		35
219	VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. 2007 , 81, 185-93		87
218	Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands. 2007 , 29, 671-5		15
217	Advancement in antithrombotics for stroke prevention in atrial fibrillation. 2008 , 22, 129-37		19
216	Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. 2008 , 64, 953-60		27
215	Pharmakogenetik der oralen Antikoagulation mit Cumarinen. 2008 , 20, 230-235		2
214	Effect of tanshinone IIA on the noncovalent interaction between warfarin and human serum albumin studied by electrospray ionization mass spectrometry. 2008 , 19, 1568-75		23
213	Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 284-290	15.4	38
212	A review of albumin binding in CKD. 2008 , 51, 839-50		80

211	Pharmacogenetics of oral anticoagulants: a basis for dose individualization. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 565-94	6.2	81
210	VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. <i>Pharmacogenomics</i> , 2008 , 9, 1631-8	2.6	45
209	Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion. 2008 , 6, 173-7		5
208	The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon. 2008 , 123, 225-30		28
207	Pharmacogenomics of 4-hydroxycoumarin anticoagulants. 2008 , 40, 355-75		79
206	Pharmacogenomics in acute coronary syndrome. 2008 , 9, 363-76		2
205	Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. 2008 , 46, 146-7		29
204	Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers. 2008 , 24, 2449-56		7
203	Genetic variations and their influence on risk and treatment of venous thrombosis. <i>Pharmacogenomics</i> , 2008 , 9, 423-37	2.6	4
202	Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. <i>Pharmacogenomics</i> , 2008 , 9, 1237-50	2.6	34
201	Warfarin therapy: in need of improvement after all these years. 2008 , 9, 677-86		54
200	Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin. 2009 , 49, 1157-67		15
199	Thrice weekly warfarin administration in haemodialysis patients. 2009 , 24, 3162-7		12
198	Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing. 2009 , 65, 783-8		6
197	Therapeutic efficacy of acenocoumarol in a warfarin-resistant patient with deep venous thrombosis: a case report. 2009 , 65, 1265-6		2
196	Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension. 2009 , 39 Suppl 2, 14-8		7
195	Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. 2009 , 85, 379-86		26
194	Fatal intoxications by acenocoumarol, phenprocoumon and warfarin: method validation in blood using the total error approach. 2009 , 877, 2344-8		18

193	A genome-wide association study of acenocoumarol maintenance dosage. 2009 , 18, 3758-68	123
192	The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. 2009 , 49, 824-30	36
191	Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin. 2009 , 16, 215-23	5
190	Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. 2010 , 66, 253-60	39
189	VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement. 2010 , 66, 591-8	20
188	Enantioselective synthesis of coumarins catalyzed by a bifunctional amine-thiourea catalyst. 2010 , 16, 13068-71	83
187	Risk of intracerebral hemorrhage associated with phenprocoumon exposure: a nested case-control study in a large population-based German database. 2010 , 19, 722-30	21
186	Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 1012-7	15.4 16
185	Pharmacogenetics of anticoagulants. 2010 , 2010, 754919	11
184	Recent advances in oral anticoagulation for atrial fibrillation. 2010 , 4, 395-407	5
183	Tratamiento con anticoagulantes orales: inicio, ajuste y precauciones en su utilización. 2010 , 26, 17-20	1
182	Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. 2011 , 9, 279-86	14
181	Enantioselective synthesis of polycyclic coumarin derivatives catalyzed by an in situ formed primary amine-imine catalyst. 2011 , 13, 4382-5	43
180	Severe INR elevation related to duloxetine use: a case report. 2011 , 52, 583-5	3
179	Anticoagulant therapy in pregnant women with mechanical prosthetic heart valves: no easy option. 2011 , 127 Suppl 3, S56-60	57
178	Selective serotonin re-uptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment. 2011 , 72, 798-805	15
177	Transition from acenocoumarol to warfarin in a 12-year-old child. 2011 , 6, 661-4	
176	Patient knowledge of and adherence to oral anticoagulation therapy after mechanical heart-valve replacement for congenital or acquired valve defects. 2011 , 40, 139-46	26

175	Drug-drug interactions with statins: will pitavastatin overcome the statins Achilles heel?. 2011 , 27, 1551-62	41
174	Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. 2011 , 31, 249-58	30
173	Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database. 2011 , 67, 941-51	25
172	Coupling of acetonitrile deproteinization and salting-out extraction with acetonitrile stacking in chiral capillary electrophoresis for the determination of warfarin enantiomers. 2011 , 1218, 4045-51	52
171	N,N'-Dioxide-Bickel(II) complex catalyzed asymmetric Michael addition of cyclic 1,3-dicarbonyl compounds to α -unsaturated β -ketoesters. 2011 , 52, 3433-3436	45
170	Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. 2011 , 51, 1418-28	28
169	Cytochrome P450-mediated cardiovascular drug interactions. 2011 , 7, 1065-82	21
168	Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012 , 141, e326S-e350S	1175
167	A study to assess management of patients on warfarin by general dental practitioners (GDPs) in the West Midlands. 2012 , 39, 578-80, 583-4, 586-7	1
166	Renal profiles of anticoagulants. 2012 , 52, 964-75	34
165	Anticoagulation during pregnancy in patients with a prosthetic heart valve. 2012 , 9, 415-24	33
164	A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 41-53	6.2 20
163	Clinical pharmacokinetics and pharmacodynamics of vildagliptin. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 147-62	6.2 72
162	Old versus new oral anticoagulants: focus on pharmacology. 2012 , 52, 79-99	62
161	Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects. 2012 , 37, 125-32	4
160	The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. 2012 , 73, 66-76	57
159	Identification and weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care hospital. 2013 , 69, 617-27	10
158	Concurrent use of tramadol and oral vitamin K antagonists and the risk of excessive anticoagulation: a register-based nested case-control study. 2013 , 69, 641-6	11

157	Implication of novel CYP2C9*57 (p.Asn204His) variant in coumarin hypersensitivity. 2013 , 131, 535-9		7
156	Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 359-71 ^{6.2}		4
155	Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 199-209	6.2	25
154	Polymorphisms of warfarin metabolizing enzymes in an Indian population. 2013 , 51, 203		
153	Risk of subarachnoid hemorrhage and early case fatality associated with outpatient antithrombotic drug use. 2013 , 44, 2422-6		35
152	Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model. 2013 , 113, 259-65		26
151	New oral anticoagulants: comparative pharmacology with vitamin K antagonists. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 69-82	6.2	144
150	Development of a Novel Method for Warfarin Synthesis via Lipase-Catalyzed Stereoselective Michael Reaction. 2013 , 87, 1269		7
149	Enantioselective Synthesis of Coumarin Derivatives Catalyzed by Primary Amines. 2013 , 355, 3154-3160		28
148	Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment. <i>Pharmacogenomics</i> , 2013 , 14, 745-53	2.6	11
147	Stroke Pharmacogenetics. 2013 , 223-297		
146	Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm. 2013 , 23, 611-8		12
145	Pharmacogenetics of Oral Anticoagulants. 2013 , 435-467		
144	Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 1087-107	7	278
143	Metal-mediated aminocatalysis provides mild conditions: Enantioselective Michael addition mediated by primary amino catalysts and alkali-metal ions. 2013 , 9, 155-65		12
142	Comparative genetics of warfarin resistance. 2014 , 34, 143-59		19
141	Risk of bleeding and antibiotic use in patients receiving continuous phenprocoumon therapy. A case-control study nested in a large insurance- and population-based German cohort. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 912-22	7	12
140	A new algorithm for weekly phenprocoumon dose variation in a southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms. 2014 , 114, 323-9		8

139	Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. 2014 , 12, 24		37
138	Vitamin K1 in oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 2017-23	15.4	2
137	CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: influence on quality of long-term anticoagulation. 2014 , 66, 243-9		8
136	Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. 2014 , 77, 626-41		97
135	An electrochemical sensor based on multiwall carbon nanotubes and molecular imprinting strategy for warfarin recognition and determination. 2014 , 196, 539-545		70
134	Synthesis of 4-hydroxy-3-[(E)-2-(6-substituted-9H-purin-9-yl)vinyl]coumarins as lipoxygenase inhibitors. 2014 , 55, 650-653		4
133	Interaction between Levothyroxine and Phenprocoumon: a case report. 2014 , 9, 231-234		1
132	Efficient C-3 reductive alkylation of 4-hydroxycoumarin by dehydrogenative oxidation of benzylic alcohols through ruthenium catalysis. 2014 , 38, 1794		18
131	Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece. 2014 , 12, 5		12
130	Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms. 2014 , 134, 604-9		18
129	Pharmacoepidemiological assessment of drug interactions with vitamin K antagonists. 2014 , 23, 1160-7		11
128	Control de la anticoagulación con warfarina o acenocoumarol en España. ¿Hay diferencias?. 2015 , 68, 1181-1182		14
127	The effect of acenocoumarol on the antiplatelet effect of clopidogrel. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 708-16	7	3
126	Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. 2015 , 17, 840-54		25
125	Control of Anticoagulation With Warfarin or Acenocoumarol in Spain. Do They Differ?. 2015 , 68, 1181-2		5
124	Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trials. 2015 , 94, 189-200		5
123	P-glycoprotein: a clue to vitamin K antagonist stabilization. <i>Pharmacogenomics</i> , 2015 , 16, 129-36	2.6	4
122	Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro. 2015 , 49, 842-53		18

121	Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting. 2015 , 35, 455-61	6
120	Extrapolation of acenocoumarol pharmacogenetic algorithms. 2015 , 74, 151-157	5
119	Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients. 2015 , 26, 167-74	6
118	Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon. 2015 , 71, 1461-5	2
117	Pharmacogenetics of Coumarin Anticoagulant Therapy. 2015 , 307-328	2
116	Farmacogenética: Aplicaciones cardiovasculares. 2015 , 26, 198-209	3
115	Design, Synthesis and Antifungal Activity of Coumarin Ring-Opening Derivatives. 2016 , 21,	12
114	Reversing vitamin K antagonists: making the old new again. 2016 , 2016, 605-611	6
113	A novel sensitive and selective electrochemical sensor based on molecularly imprinted polymer on a nanoporous gold leaf modified electrode for warfarin sodium determination. 2016 , 6, 43724-43731	29
112	Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network. 2016 , 5, 554-564	9
111	Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin. 2016 , 50, 909-917	21
110	Synthesis of Some Novel 4-Methylumbelliferone Derivatives. 2016 , 86, 313-321	
109	Microwave-assisted Synthesis and antifungal activity of coumarin[8,7-e][1,3]oxazine derivatives. 2016 , 20, 611-8	17
108	Synthesis of C3-dihydrofuran substituted coumarins via multicomponent approach. 2016 , 46, 613-619	11
107	R- and S-Warfarin Were Transported by Breast Cancer Resistance Protein: From In Vitro to Pharmacokinetic-Pharmacodynamic Studies. 2017 , 106, 1419-1425	10
106	Enzyme-catalyzed Michael addition for the synthesis of warfarin and its determination via fluorescence quenching of l-tryptophan. 2017 , 176, 183-188	14
105	Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. 2017 , 43, 365-379	62
104	Sensitive warfarin sensor based on cobalt oxide nanoparticles electrodeposited at multi-walled carbon nanotubes modified glassy carbon electrode (CoxOyNPs/MWCNTs/GCE). 2017 , 246, 689-698	18

103	Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS. 2017 , 55, 1349-1359		23
102	Role of ABC transporters in trans-epithelial transport of vitamin K antagonists. 2017 , 38, 20-32		3
101	Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 454-464	15.4	2
100	Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation. 2017 , 34, 2274-2294		4
99	Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 139-152	6.2	45
98	Investigating the Effects of Rare Variants in Concurrent Drug Usage: An Association Analysis Approach. 2017 ,		
97	Pharmacogenetic Variation in Over 100 Genes in Patients Receiving Acenocoumarol. 2017 , 8, 863		4
96	Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1267-1293	6.2	17
95	Development of a clinical prediction model for an international normalised ratio 415 in hospitalised patients using vitamin K antagonists. 2018 , 181, 102-110		
94	Impact of pre-admission oral anticoagulation on ischaemic stroke volume, lesion pattern, and frequency of intracranial arterial occlusion in patients with atrial fibrillation: simplicity to complexity and refining the need to try harder?. 2018 , 20, 1711-1713		
93	Enzyme-linked immunosorbent assays for therapeutic drug monitoring coumarin oral anticoagulants in plasma. 2018 , 1028, 59-65		7
92	The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats. 2018 , 48, 400-406		10
91	[Oral anticoagulation using coumarins - an update]. 2018 , 168, 121-132		0
90	Proposed Criteria for the Use of Low-Dose Vitamin K Supplementation in Patients Using Vitamin K Antagonists: A Literature Review of a Clinical Controversy. 2018 , 31, 208-215		1
89	Introduction of Nature's Complexity in Engineered Blood-compatible Biomaterials. 2018 , 7, 1700505		29
88	Biobarcode assay for the oral anticoagulant acenocoumarol. 2018 , 178, 308-314		4
87	Perioperative Management of Antithrombotic Therapy in the Periprocedural Period of Patients Undergoing Hysterectomy. 2018 , 299-305		0
86	Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice. 2018 , 84, 590-601		8

85	Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants. 2018 , 9, 29238-29258	18
84	VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites. 2018 , 2, 691-702	9
83	Oral anticoagulation and left atrial thrombi resolution in nonrheumatic atrial fibrillation or flutter: A systematic review and meta-analysis. 2018 , 41, 767-774	8
82	VKORC1L1, An Enzyme Mediating the Effect of Vitamin K in Liver and Extrahepatic Tissues. 2018 , 10,	10
81	Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. 2017 , 8,	86
80	Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences. 2018 , 129, 102-112	31
79	Dicoumarol derivatives: Green synthesis and molecular modelling studies of their anti-LOX activity. 2018 , 80, 741-752	9
78	Absorption des médicaments lors de syndrome du grêle court. 2018 , 32, 143-149	
77	Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). 2018 , 135, 60-79	57
76	Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu. 2018 , 132, 1974-1984	15
75	Treatment Expectations, Convenience, and Satisfaction with Anticoagulant Treatment: Perceptions of Patients in South-East Queensland, Australia. 2019 , 8,	2
74	Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications. 2019 , 19, 501-515	9
73	Oral Anticoagulant Therapy-When Art Meets Science. 2019 , 8,	6
72	Quantification of apixaban in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry. 2019 , 27, 33-41	2
71	Getting to the Heart of the Matter: A Review of Drug Interactions Between HIV Antiretrovirals and Cardiology Medications. 2019 , 35, 326-340	10
70	Decreased warfarin sensitivity among patients treated with elbasvir and grazoprevir for hepatitis C infection. 2019 , 76, 1273-1280	1
69	Anti-embolic and anti-oxidative effects of a novel (E)-4-amino-NP(1-(7-hydroxy-2-oxo-2H-chromen-3-yl) ethylidene) benzohydrazide against isoproterenol and vitamin-K induced ischemic stroke. 2021 , 127, 527-540	4
68	Conjugate Addition of Carbon Acids to α -Unsaturated β -Keto Esters: Product Tautomerism and Applications for Asymmetric Synthesis of Benzo α -phenazin-5-ol Derivatives. 2019 , 84, 13824-13831	7

67	Cyclooctatetraene: A Bioactive Cubane Paradigm Complement. 2019 , 25, 2729-2734	17
66	Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies. 2019 , 42, 1135-1148	13
65	Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients. 2019 , 74, 2848-2864	4
64	An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials. <i>Drug Metabolism and Disposition</i> , 2019 , 47, 601-614	18
63	Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. 2019 , 15, 381-398	21
62	Periprocedural Management of Anticoagulation in Patients With Atrial Fibrillation. 2019 , 105-119	
61	Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects. 2020 , 20, 104-113	8
60	Plasma Metabolites as Predictors of Warfarin Outcome in Atrial Fibrillation. 2020 , 20, 169-177	5
59	Piperine Alters the Pharmacokinetics and Anticoagulation of Warfarin in Rats. 2020 , 12, 169-179	6
58	Clopidogrel drug interactions: a review of the evidence and clinical implications. 2020 , 16, 1079-1096	2
57	A Brief Review on Determination of Acenocoumarol in Biological and Pharmaceutical Specimens: Analytical Methodologies. 2020 , 1-10	1
56	[Adverse drug reactions profiles for abiraterone and enzalutamide: A pharmacovigilance descriptive analysis]. 2021 , 76, 455-465	1
55	(E)-NP(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide protecting rat heart tissues from isoproterenol toxicity: Evidence from in vitro and in vivo tests. 2020 , 881, 173137	2
54	Coumarin as a structural component of substrates and probes for serine and cysteine proteases. 2020 , 1868, 140445	11
53	(E)-NP(1-(7-Hydroxy-2-Oxo-2H-Chromen-3-Yl) Ethylidene) Benzohydrazide, a Novel Synthesized Coumarin, Ameliorates Isoproterenol-Induced Myocardial Infarction in Rats through Attenuating Oxidative Stress, Inflammation, and Apoptosis. 2020 , 2020, 2432918	5
52	Genome-Wide Association Study of VKORC1 and CYP2C9 on acenocoumarol dose, stroke recurrence and intracranial haemorrhage in Spain. 2020 , 10, 2806	4
51	Simultaneous determination of warfarin and 7-hydroxywarfarin in rat plasma by HPLC-FLD. 2020 , 70, 343-357	2
50	The Magnitude of the Warfarin-Amiodarone Drug-Drug Interaction Varies With Renal Function: A Propensity-Matched Cohort Study. 2020 , 107, 1446-1456	0

- 49 Potential effect of new (E)-4-hydroxy -NP(1-(7-hydroxy-2-oxo-2H-chromen-3-yl) ethylidene) benzohydrazide against acute myocardial infarction: Haemodynamic, biochemical and histological studies. **2020**, 1
- 48 Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications. **2021**, 35, 427-440 9
- 47 Two Strategies for the Dosage of Acenocoumarol Co-Administered with Rifampicin in Staphylococcal Prosthetic Valve Endocarditis. **2021**, 10,
- 46 Bleeding Risk in Randomized Controlled Trials Comparing Aspirin, Clopidogrel, and Vitamin K Antagonists: A Network Meta-analysis of 204,989 Patients. **2021**, 28, e156-e162
- 45 Performance Characteristics of DOAC Dipstick in Determining Direct Oral Anticoagulants in Urine. **2021**, 27, 1076029621993550 4
- 44 Risk of over-anticoagulation during acute kidney injury in patients treated with vitamin K antagonists. **2021**, 0
- 43 Neurochirurgische Intensivmedizin bei älteren Patienten. **2021**, 81-93
- 42 Drug-drug interactions between vitamin K antagonists and statins: a systematic review. **2021**, 77, 1435-1441 2
- 41 Anticoagulation Control with Acenocoumarol or Warfarin in Non-Valvular Atrial Fibrillation in Primary Care (Fantas-TIC Study). **2021**, 18, 1
- 40 An efficient approach for the synthesis and antimicrobial evaluation of some new benzocoumarins and related compounds. **2021**, 51, 2175-2186
- 39 Applied Nanotechnologies in Anticoagulant Therapy: From Anticoagulants to Coagulation Test Performance of Drug Delivery Systems. **2021**, 2, 98-117 1
- 38 Design, multistep synthesis and in-vitro antimicrobial and antioxidant screening of coumarin clubbed chalcone hybrids through molecular hybridization approach. **2021**, 14, 103154 6
- 37 Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta-analysis. **2021**, 44, 1208-1215 4
- 36 Natural Coumarins: Exploring the Pharmacological Complexity and Underlying Molecular Mechanisms. **2021**, 2021, 6492346 9
- 35 Biomodification of acenocoumarol by bifidobacteria. **2021**, 368, 1
- 34 Contribution of Crop Biofortification in Mitigating Vitamin Deficiency Globally. **2021**, 112-130 1
- 33 Management of cancer-associated venous thromboembolism - a case-based practical approach. **2018**, 47, 77-89 12
- 32 Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With and Polymorphisms. **2019**, 10, 1620 1

31	Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy. 2020 , 10,	7	
30	Active Forms, Antagonists, Physical Properties, and Synthesis of Vitamin K. 2009 , 13-37		
29	Oral anticoagulants. 2011 , 319-327		
28	Pharmacology of Vitamin K Antagonists. 25-46		
27	Stroke Pharmacogenetics. 2017 , 327-410		
26	Non-Obvious, Post-Traumatic, Life-Threatening Bleeding in Two Elderly Patients. <i>The Journal of Critical Care Medicine</i> , 2017 , 3, 79-83	1.2	
25	Coagulation and Anticoagulants. 2020 , 1-53		
24	Anticoagulants and Antiplatelet Drugs. 2021 ,		
23	Anticoagulant rodenticide ingestion: Who will develop coagulopathy?. <i>Hong Kong Journal of Emergency Medicine</i> , 102490792110499	0.4	
22	Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 284-90	15.4	12
21	Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G. <i>Indian Journal of Medical Research</i> , 2013 , 137, 203-9	2.9	7
20	The influence of excessive consumption of liquorice on phenprocoumon (Marcumar®): a case report. <i>Journal of International Medical Research</i> , 2021 , 49, 3000605211049649	1.4	1
19	Arzneimitteltherapiesicherheit: Interaktionspotenzial der oralen Antikoagulanzen.		
18	The value and limitations of new oral anticoagulant plasma level assessments.. <i>European Heart Journal Supplements</i> , 2022 , 24, A32-A41	1.5	0
17	Development of a Fluorescent Microfluidic Device Based on Antibody Microarray Read-Out for Therapeutic Drug Monitoring of Acenocoumarol.. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022 , 10, 848501	5.8	1
16	The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists.. <i>Thrombosis and Haemostasis</i> , 2022 , 122, 377-385	7	0
15	DataSheet_1.docx. 2020 ,		
14	[Safety and effectiveness of oral anticoagulation in patients with atrial fibrillation and renal insufficiency - a real-world perspective].. <i>Deutsche Medizinische Wochenschrift</i> , 2022 , 147, 617-624	0	

13	Pharmacogenetic variants influence vitamin K anticoagulant dosing in patients with mechanical prosthetic heart valves. <i>Pharmacogenomics</i> , 2022 , 23, 475-485	2.6	
12	Warfarin resistance: possibilities to solve this problem. A case report. <i>Journal of International Medical Research</i> , 2022 , 50, 030006052211039	1.4	
11	Pharmacokinetic Modeling of Warfarin □ Model-based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals CYP2C9 Genotype-dependent Drug-drug Interactions of S-Warfarin. <i>Drug Metabolism and Disposition</i> , DMD-AR-2022-000876	4	1
10	Pharmacokinetic Modeling of Warfarin □- Model-based Analysis of Warfarin Metabolites following Warfarin Administered either Alone or Together with Fluconazole or Rifampin. <i>Drug Metabolism and Disposition</i> , DMD-AR-2022-000877	4	0
9	Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. 2022 ,		3
8	Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. 2022 ,		0
7	Selective serotonin reuptake inhibitor use and risk of major bleeding during treatment with vitamin K antagonists: results of a cohort study.		0
6	A physiological-based pharmacokinetic model embedded with a target-mediated drug disposition mechanism can characterize single dose warfarin pharmacokinetic profiles in subjects with various CYP2C9 genotypes under different co-treatments. DMD-AR-2022-001048		0
5	Frequency of Hemorrhagic Side Effects of Botulinum Neurotoxin Treatment in Patients with Blepharospasm and Hemifacial Spasm on Antithrombotic Medication. 2022 , 14, 769		0
4	Electrochemical Analysis of Metabolites as a Method for Cytochromes P450 Activity Determination. 2022 , 5, e00176		0
3	Pharmacokinetics of Phenprocoumon in Emergency Situations□Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry). 2022 , 15, 1437		0
2	Gerinnungsmanagement in der schweren, fortgeschrittenen Niereninsuffizienz. 2022 , 11, 537-542		0
1	Exploring the potential impact of probiotic use on drug metabolism and efficacy. 2023 , 161, 114468		0